Sai Parenteral IPO

Sai Parenteral's Ltd. (SPL) is tapping the market with an IPO between March 24-27, 2026, aiming to raise ₹408.79 crore. This diversified pharmaceutical company excels in branded generic formulations and Contract Development and Manufacturing Organisation (CDMO) products, serving both domestic and international markets. A significant recent move includes acquiring a 74.60% stake in Australia's Noumed Pharmaceuticals in November 2025, which promises to expand its global reach and intellectual property, boosting its impressive portfolio of over 500 dossiers. Financially, SPL shows robust growth, with FY25 net profit at ₹14.45 crore on ₹163.74 crore total income. While the IPO's valuation, at a P/E of nearly 120 based on FY25 earnings, appears on the higher side, the company's strategic acquisitions and ongoing capacity enhancements position it for considerable top and bottom-line growth. For well-informed investors, this offering presents a promising opportunity for medium to long-term investment.